Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Obese Patients with Knee Osteoarthritis
NCT02931383Phase 4Completed
- Start
- Nov 2016
- Primary completion
- Feb 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity and osteoarthritis (OA) comparing Liraglutide 3 mg with Placebo (2 arms). Primary endpoint: Change in the degree of inflammation in the knee-joint (Greyscale-score). Started Nov 2016; status: completed.
02
Drugs
03
Conditions
obesityosteoarthritis (OA)
Beyond the preview
Go deeper on NCT02931383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931383.